168 related articles for article (PubMed ID: 12009273)
1. Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus gordonii vaccine vectors.
Byrd CM; Bolken TC; Jones KF; Warren TK; Vella AT; McDonald J; King D; Blackwood Z; Hruby DE
Vaccine; 2002 May; 20(17-18):2197-205. PubMed ID: 12009273
[TBL] [Abstract][Full Text] [Related]
2. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.
Mansour NM; Abdelaziz SA
Microbiol Immunol; 2016 Aug; 60(8):527-32. PubMed ID: 27301486
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ
Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945
[TBL] [Abstract][Full Text] [Related]
4. Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccine.
García PC; Paillavil BA; Scioscia N; Dale JB; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM; Wozniak A
Microbiol Immunol; 2018 Nov; 62(11):711-719. PubMed ID: 30357922
[TBL] [Abstract][Full Text] [Related]
5. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
[TBL] [Abstract][Full Text] [Related]
6. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
Smeesters PR; Dramaix M; Van Melderen L
Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033
[No Abstract] [Full Text] [Related]
7. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
Wozniak A; Scioscia N; García PC; Dale JB; Paillavil BA; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM
Microbiol Immunol; 2018 Jun; 62(6):395-404. PubMed ID: 29704396
[TBL] [Abstract][Full Text] [Related]
8. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
Mannam P; Jones KF; Geller BL
Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
[TBL] [Abstract][Full Text] [Related]
9. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
Good MF; Pandey M; Batzloff MR; Tyrrell GJ
Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
[TBL] [Abstract][Full Text] [Related]
10. Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine.
Kotloff KL; Wasserman SS; Jones KF; Livio S; Hruby DE; Franke CA; Fischetti VA
Infect Immun; 2005 Apr; 73(4):2360-6. PubMed ID: 15784582
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
[TBL] [Abstract][Full Text] [Related]
12. Molecular biology of Group A
Brahmadathan NK
Indian J Med Microbiol; 2017; 35(2):176-183. PubMed ID: 28681803
[TBL] [Abstract][Full Text] [Related]
13. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
[TBL] [Abstract][Full Text] [Related]
14. Similar ability of FbaA with M protein to elicit protective immunity against group A streptococcus challenge in mice.
Ma CQ; Li CH; Wang XR; Zeng RH; Yin XL; Feng HD; Wei L
Cell Mol Immunol; 2009 Feb; 6(1):73-7. PubMed ID: 19254483
[TBL] [Abstract][Full Text] [Related]
15. The quest for GAS vaccine.
Pandey M; Good MF
Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764
[No Abstract] [Full Text] [Related]
16. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of amino acids 1-150 of Streptococcus GapC displayed on the surface of Escherichia coli.
Song B; Yang X; Sun H; Yu L; Ma J; Wu Z; Cui Y
Microb Pathog; 2017 Apr; 105():288-297. PubMed ID: 28179116
[TBL] [Abstract][Full Text] [Related]
18. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
[TBL] [Abstract][Full Text] [Related]
19. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
Smeesters PR; McMillan DJ; Sriprakash KS; Georgousakis MM
Expert Rev Vaccines; 2009 Dec; 8(12):1705-20. PubMed ID: 19905872
[TBL] [Abstract][Full Text] [Related]
20. Immunity to group a streptococcal M proteins: forging a single-edged sword.
Madoff LC
Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630
[No Abstract] [Full Text] [Related]
[Next] [New Search]